Organogenesis lowered 2026 guidance. Organogenesis stock fell 2.56 percent

Organogenesis stock (ISIN US68621F1021) was EUR 1.14 at Lang & Schwarz on October 8, 2026 in after-hours trading, down 2.56 percent versus the prior close of EUR 1.17. The regenerative medicine company had lowered its 2026 revenue outlook after a weak second quarter, according to Webull reports dated August 7, 2026.

Second-quarter revenue fell sharply

Organogenesis reported second-quarter 2026 revenue of USD 43.76 million on August 6, 2026, down 56.70 percent from the year-earlier period. The result was also 19.38 percent below consensus revenue of USD 54.27 million, based on figures published by ToAlpha.

The company posted a USD 96.27 million GAAP net loss in the second quarter of 2026, compared with a USD 53.16 million loss in the first quarter. Operating margin was negative 117.00 percent in the second quarter, while operating cash flow was negative USD 31.65 million for the period.

What does the guidance reset mean?

The revised outlook points to a slower recovery path. Management still expected sequential improvement in the third and fourth quarters, but the second-quarter revenue decline and the wider loss placed greater weight on cost reductions and the timing of demand recovery.

The earnings picture also explains the market reaction to the outlook change. The second-quarter adjusted net loss was USD 89.00 million, while the GAAP loss included a USD 30.00 million non-cash tax expense tied to a valuation allowance on deferred tax assets, according to the August 6, 2026 earnings coverage from Webull.

Analyst target remains above Nasdaq price

Truist maintained a Hold rating but lowered its price target from USD 3.00 to USD 2.00 on August 7, 2026, as reported by Webull. The revised target remained 57.48 percent above the EUR 1.14 Lang & Schwarz price only if currencies are ignored, so the comparison is kept separate: at Nasdaq, the stock was last at USD 1.27 on October 8, 2026 at 1:47 p.m. ET, with a market capitalization of USD 164.1 million.

Next reporting date is November 5

The next reporting date listed for Organogenesis is November 5, 2026, according to ToAlpha. The Nasdaq quote was inside the USD 1.25 to USD 7.08 52-week range on October 8, 2026, leaving the next results release as the clearest scheduled test of the recovery outlook.

After-hours quote remains under pressure

Organogenesis was at EUR 1.14 at Lang & Schwarz on October 8, 2026, down 2.56 percent from the EUR 1.17 prior close dated October 7, 2026. The Nasdaq context was USD 1.27, with the US session still open at the quoted time. The further course of trading is shown by the continuously updated real-time quote of Organogenesis stock.

Market context: Market report Nasdaq Composite.

More news and analyses on Organogenesis stock